450
Participants
Start Date
September 30, 2006
Primary Completion Date
April 30, 2008
Study Completion Date
April 30, 2008
Quetiapine XR
Quetiapine XR 50 mg tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily, in the evening for a 9-week treatment period.
Placebo
Matching placebo tablets orally administered in flexible doses of 50 to 300 mg once daily, in the evening for a 9-week treatment period.
Research Site, Fort Myers
Research Site, Gainsville
Research Site, Miami
Research Site, Sarasota
Research Site, Roswell
Research Site, Boston
Research Site, Brooklyn
Research Site, The Bronx
Research Site, Avon Lake
Research Site, Eugene
Research Site, Jenkintown
Research Site, Austin
Research Site, Houston
Research Site, San Antonio
Research Site, Tartu
Research Site, Tallinn
Research Site, Viljandi
Research Site, Bialystok
Research Site, Gorlice
Research Site, Katowice
Research Site, Krakow
Research Site, Leszno
Research Site, Skorzewo
Research Site, Torun
Research Site, Wroclaw
Research Site, Arkhangelsk
Research Site, Izhevsk
Research Site, Lipetsk
Research Site, Moscow
Research Site, Nizhny Novgorod
Research Site, Perm
Research Site, Saint Petersburg
Research Site, Saratov
Research Site, Stavropol
Research Site, Voronezh
Research Site, Hlevakha
Research Site, Dnipro
Research Site, Dnipropetrovsk
Research Site, Donetsk
Research Site, Kiev
Research Site, Luhansk
Research Site, Odesa
Research Site, Vinnitsa
Lead Sponsor
AstraZeneca
INDUSTRY